Disease · HP_0002902
Comparisons in its trials37
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 37
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Tolvaptan 15-60 mg/Day vs Placebo: serious adverse events | 18 of 66 | 9 of 55 | 121 | NCT01227512 | Trial comparisons |
| Hypotonic vs Isotonic: serious adverse events | 4 of 34 | 0 of 32 | 66 | NCT01301274 | Trial comparisons |
| Hypotonic Arm vs Isotonic Arm: Mortality at 28 Days | 3 of 32 | 0 of 31 | 63 | NCT01301274 | Trial comparisons |
| ClNa 0.3% vs ClNa 0.45%: serious adverse events | 0 of 29 | 0 of 29 | 58 | NCT01251770 | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Serum Chemistry Laboratory Abnormalities: Glucose | 0 of 29 | 2 of 28 | 57 | NCT00550459 | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Serum Chemistry Laboratory Abnormalities: Blood Urea Nitrogen (BUN) | 2 of 29 | 1 of 28 | 57 | NCT00550459 | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Electrocardiogram (ECG) Abnormalities: ST Segment | 2 of 29 | 0 of 28 | 57 | NCT00550459 | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Vital Sign Abnormalities: Pulse Rate | 0 of 29 | 0 of 28 | 57 | NCT00550459 | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Electrocardiogram (ECG) Abnormalities: QRS Interval | 1 of 29 | 1 of 28 | 57 | NCT00550459 | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Vital Sign Abnormalities: Blood Pressure | 0 of 29 | 2 of 28 | 57 | NCT00550459 | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Serum Chemistry Laboratory Abnormalities: Cholesterol | 2 of 29 | 0 of 28 | 57 | NCT00550459 | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Vital Sign Abnormalities: Body Temperature | 0 of 29 | 1 of 28 | 57 | NCT00550459 | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Serum Chemistry Laboratory Abnormalities: Uric Acid | 1 of 29 | 0 of 28 | 57 | NCT00550459 | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcB Increase 30-60 Msec | 4 of 29 | 3 of 28 | 57 | NCT00550459 | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Serum Chemistry Laboratory Abnormalities: Magnesium | 1 of 29 | 0 of 28 | 57 | NCT00550459 | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Electrocardiogram (ECG) Abnormalities: Arrhythmia | 6 of 29 | 2 of 28 | 57 | NCT00550459 | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Electrocardiogram (ECG) Abnormalities: Right Bundle Branch Block (RBBB), Left Bundle Branch Block (LBBB), Myocardial Infarction (MI) | 1 of 29 | 0 of 28 | 57 | NCT00550459 | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcF Increase 30-60 Msec | 3 of 29 | 2 of 28 | 57 | NCT00550459 | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Electrocardiogram (ECG) Abnormalities: QT >500 Milliseconds (Msec) | 0 of 29 | 1 of 28 | 57 | NCT00550459 | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Electrocardiogram (ECG) Abnormalities: T Wave | 1 of 29 | 1 of 28 | 57 | NCT00550459 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/HP_0002902/comparisons